02091nam a2200277   4500001000800000005001700008007000300025008004100028040000800069041000800077100003600085245010600121300002500227520112000252650001801372650003301390650003201423650004301455650004701498650004601545700003101591700003301622773011001655942003101765999001701796ESSALUD20260903091623.0ta      t        pe ||||| |||| 00| 0 spa d  aBMG  aeng  aHwang, Thomas J. eAutor954498  aReforming payment for clinician-administered drugs — Most-favored-nation pricing in medicare Part B  apáginas: 1774-1777  aAddressing escalating spending on prescription drugs by Medicare Part B, which covers clinician-administered drugs, has been a top U.S. policy priority. On December 19, 2025, the Trump administration announced a new payment model to align Medicare Part B fee-for-service payments for prescription drugs with international pricing benchmarks. This proposal — the Global Benchmark for Efficient Drug Pricing (GLOBE) model — was released alongside parallel most-favored-nation pricing models for Medicare Part D (Guarding U.S. Medicare against Rising Drug Costs, or GUARD) and Medicaid (Generating Cost Reductions for U.S. Medicaid, or GENEROUS). These announcements followed a May 2025 executive order calling for most-favored-nation pricing and previous efforts by the Obama administration and the first Trump administration to control Part B spending. If implemented, the GLOBE model could reduce costs for Medicare beneficiaries, taxpayers, and the Medicare program. But exceptions could limit participation in the model, and, in the absence of safeguards, its provisions could alter incentives for innovation.  aALERGIA97055  aINMUNOLOGÍA GENERAL953664  aEFICACIA COMPARATIVA954499  aCOSTO DE LA ATENCIÓN MÉDICA954150  aMEDICAMENTOS, DISPOSITIVOS Y LA FDA954223  aPOLÍTICA SANITARIA INTERNACIONAL954131  aClemans-Cope, Lisa 954500  aKesselheim, Aaron S. 9545010 022717922676dMassachusetts NEJM GroupoNEJM015tThe New England Journal of Medicine wESSALUDx0028-4793  cARTICULOSe2026-08-31zsqb  c22912d22912